Back to search results
NCT07582523

Out-of-office Monitoring for Rhythms Of Normal Versus Atrial Fibrillation

Enrolling by Invitation
NAAges 60+InterventionalScreening
University of California, San Francisco
~1,910 participants
Updated 2026-05-13 on ClinicalTrials.gov
What's tested:Blood Pressure Monitor Without AFib DetectionBlood Pressure Monitor With AFib Detection

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to first AFib diagnosis within 6 months after randomization
Measured over Throughout and up to 6-months post randomization

Conditions

Atrial Fibrillation (AF)
Hypertension (HTN)
High Blood Pressure

Explore related trials

Atrial FibrillationHypertension

NCT07582523

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UCSF Medical Center at Parnassus

    San Francisco, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Gregory M Marcus, MD, MAS · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

≥70 years old
BMI ≥30kg/m2
CHA2DS2-VASc ≥3 (excluding Female sex)

Exclusion

Current or prior diagnosis of atrial fibrillation (AFib), atrial flutter, or atrial tachycardia
Receiving anticoagulation therapy
History of skin allergies to adhesive patches
Open wound or skin inflammation, such as eczema, in the chest region.
Inability to wear the patch ECG monitor or apply the monitor by herself/himself or with the help of a caregiver
Individuals who are currently using home medical devices or wearable devices capable of detecting atrial fibrillation and are unwilling to refrain from using such AF detection device features during the randomized controlled trial (RCT) phase of the study
People who have a mailing address in Alaska, Hawaii, or a U.S. territory

What this trial measures

  • Time to first AFib diagnosis within 6 months after randomizationThroughout and up to 6-months post randomization

    The primary outcome will be time to AFib diagnosis, defined as the earliest AFib confirmed on a study continuously-recording ECG patch, or AFib clinically diagnosed during usual care (recorded by a treating clinician in the medical record, independent of study ECG patch confirmation).